Vision, Integrity, Expertise

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, acute radiation syndrome, and emerging and antibiotic resistant infectious disease.

Corporate Presentation
March 12, 2018

View the presentation (pdf)

Watch the video on YouTube

Investor Update Letter
January 25, 2018

Read the letter (pdf)

 
* * Latest News Latest News
 
* * Relevant Publications Publications
 
* * Presentations Presentations

Innate defense regulators: Broad-spectrum, host-directed therapy for antibiotic resistant disease
November 13, 2017

Watch the presentation on YouTube


Innate Defense Regulator Peptides: A Novel Mechanism with Broad Applicability in Multiple Disease Indications
October 27, 2017

View the presentation (pdf)


Therapeutic Applications of Innate Immune Modulation
October 9, 2017

Watch the presentation on YouTube

Show more >

* Presentations

Innate defense regulators: Broad-spectrum, host-directed therapy for antibiotic resistant disease
November 13, 2017

Watch the presentation on YouTube


Innate Defense Regulator Peptides: A Novel Mechanism with Broad Applicability in Multiple Disease Indications
October 27, 2017

View the presentation (pdf)


Therapeutic Applications of Innate Immune Modulation
October 9, 2017

Watch the presentation on YouTube

Show more >

Our Clinical Trials

Learn more >

Partnering with Us

Learn more >